AZ's Alexion inks $125M deal to resolve investor lawsuit over Soliris sales tactics

Nearly seven years have passed since Alexion’s then-CEO and CFO stepped down amid an investigation into improper sales practices. Now, the rare disease specialist can put the episode completely in the rearview mirror thanks to a settlement with investors.